

Sabino De Placido

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/37175/sabino-de-placido-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191
papers

5,943
citations

43
h-index

70
g-index

212
ext. papers

7,347
ext. citations

5.2
avg, IF

5.37
L-index

#	Paper	IF	Citations
191	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. <i>Cancer Research</i> , 2022 , 82, P3-09-03-P3-09-03	10.1	0
190	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103649	7	1
189	Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.. <i>Frontiers in Oncology</i> , 2021 , 11, 754108	5.3	0
188	Pneumonitis in patients with thymoma and Good's syndrome.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e20595-e20595	2.2	0
187	Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 355-366	2.5	1
186	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 149, 134-152	7.5	13
185	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021 , 26, e1854-e1861	5.7	1
184	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 82	7.8	0
183	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103191	7	3
182	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
181	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 1	7.8	54
180	Case Report: Detection of a Novel Germline Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. <i>Frontiers in Oncology</i> , 2021 , 11, 602523	5.3	3
179	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	4
178	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
177	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 1458-1467	21.7	7
176	Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e286-e298	3.3	6
175	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1089-1097	9.7	25

174	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020 , 182, 401-409	4.4	10
173	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 270-276	3.8	
172	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020 , 20, 232	4.8	1
171	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020 , 136, 43-51	7.5	3
170	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919899850	5.4	1
169	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	19
168	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
167	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020 , 50, 56-63	3.6	3
166	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020 , 11, 2083-2091	3.3	5
165	Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020 , 12, 456-460	1.6	1
164	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
163	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920947970	5.4	3
162	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020 , 5, e000885	6	5
161	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABITUDE study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968725	5.4	3
160	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 83	8.3	4
159	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020 , 25, e1509-e1515	5.7	7
158	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists 2020 , 8,		4
157	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020 , 5,	6	18

156	A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020 , 10, 602153	5.3	3
155	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019 , 11,	6.6	12
154	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology, The</i> , 2019 , 20, 1360-1369	21.7	68
153	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 118, 178-186	7.5	23
152	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019 , 154, 83-88	4.9	4
151	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
150	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019 , 38, 307-313	9.6	21
149	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. <i>Cancers</i> , 2019 , 11,	6.6	19
148	Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2019 , 20, 1345-1352	4.1	33
147	Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019 , 25, 1310-1311	1.2	2
146	Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 937-944	2.5	12
145	Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12549-e12549	2.2	0
144	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12528-e12528	2.2	
143	Anti-EGFR target therapy in advanced thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8567-8567	2.2	
142	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 421-432	5.1	28
141	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019 , 24, 385-393	5.7	15
140	Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour. <i>Anti-Cancer Drugs</i> , 2019 , 30, 959-963	2.4	2
139	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019 , 73, 73-83	14.4	62

138	Epigenetic Silencing of Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44/CD24/CD90 Myoepithelial Cells. <i>Molecular Cancer Research</i> , 2019 , 17, 628-641	6.6	2
137	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 474-485	21.7	39
136	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018 , 78, 845-852	10.1	111
135	Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. <i>Menopause</i> , 2018 , 25, 657-662	2.5	43
134	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018 , 38, 86-91	3.6	20
133	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
132	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018 , 9, 189	5.6	12
131	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
130	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018 , 18, 146	4.8	9
129	Long term deficiency of vitamin D in germ cell testicular cancer survivors. <i>Oncotarget</i> , 2018 , 9, 21078-21085	1.85	2
128	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 832-836	2.2	2
127	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2001-2007	2.2	82
126	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 342-349	2.2	70
125	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. <i>Medicine (United States)</i> , 2018 , 97, e11254	1.8	7
124	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018 , 8, 608	5.3	106
123	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety. <i>Molecular and Clinical Oncology</i> , 2018 , 9, 255-263	1.6	10
122	Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors. <i>Future Oncology</i> , 2018 , 14, 1591-1599	3.6	4
121	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017 , 22, 601-608	5.7	70

120	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017 , 116, 1425-1435	8.7	50
119	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
118	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
117	Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017 , 17, 559-563	3	9
116	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e3 ²⁴	3.3	24
115	2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. <i>European Heart Journal Cardiovascular Imaging</i> , 2017 , 18, 930-936	4.1	70
114	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017 , 71, 34-42	7.5	31
113	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?. <i>Breast Care</i> , 2017 , 12, 290-294	2.4	17
112	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. <i>Scientific Reports</i> , 2017 , 7, 9388	4.9	33
111	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
110	Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
109	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017 , 31, 114-120	3.6	42
108	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017 , 13, 285-293	3.6	37
107	Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?. <i>International Journal of Biological Markers</i> , 2017 , 32, e474-e477	2.8	2
106	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017 , 8, 115709-115717	3.3	11
105	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017 , 8, 112816-112824	3.3	1
104	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016 , 50, 129-141	14.4	52
103	Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2016 , 14, 18	2.3	2

102	Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. <i>Menopause</i> , 2016 , 23, 1108-13	2.5	55
101	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer 2016 , 4,		11
100	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 669-78	4.9	12
99	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016 , 12, 399-411	3.6	27
98	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016 , 14, 470-81	6.6	27
97	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016 , 7, 40073-40084	3.9	12
96	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
95	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. <i>Medicine (United States)</i> , 2016 , 95, e2754	1.8	2
94	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) 2016 , 4,		78
93	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016 , 46, 20-6	14.4	66
92	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
91	Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. <i>BMC Cancer</i> , 2016 , 16, 375	4.8	22
90	Approaches for targeting cancer stem cells drug resistance. <i>Expert Opinion on Drug Discovery</i> , 2016 , 11, 1201-1212	6.2	23
89	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
88	Treatment options in HR+/HER2? advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. <i>Future Oncology</i> , 2015 , 11, 975-81	3.6	3
87	Features of aggressive breast cancer. <i>Breast</i> , 2015 , 24, 594-600	3.6	43
86	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015 , 385, 1863-72	4.0	131
85	Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study. <i>Anti-Cancer Drugs</i> , 2015 , 26, 117-22	2.4	6

84	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015 , 26, 236-9	2.4	6
83	Mechanisms of lapatinib resistance in HER2-driven breast cancer. <i>Cancer Treatment Reviews</i> , 2015 , 41, 877-83	14.4	85
82	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
81	Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 127-32	4.4	26
80	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
79	Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015 , 27, 452-6	4.2	10
78	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13
77	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. <i>BioMed Research International</i> , 2015 , 2015, 138148	3	32
76	Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , 2015 , 41, 799-803	2.5	4
75	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015 , 94, e2117	1.8	34
74	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 534-41	7	27
73	Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015 , 41, 61-8	14.4	42
72	Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 910-5	2.2	262
71	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015 , 6, 26090-103	3.3	30
70	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 248-54	11.2	21
69	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 396-405	21.7	271
68	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014 , 23, 69-75	3.6	72
67	Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 185-91	3.8	20

66	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014 , 10, 1353-60	3.6	21
65	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014 , 16, 440	8.3	77
64	Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. <i>BioMed Research International</i> , 2014 , 2014, 840921	3	46
63	Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014 , 10, 845-50	3.6	2
62	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014 , 16, R45	8.3	49
61	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014 , 2, 228-31	1.6	15
60	Breast cancer subtypes according to body mass index and insulin resistance.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 571-571	2.2	
59	Risk factors for cancer-related venous thromboembolism in ambulatory patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20625-e20625	2.2	
58	Bevacizumab maintenance in metastatic colorectal cancer: How long?. <i>World Journal of Clinical Cases</i> , 2014 , 2, 717-23	1.6	
57	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013 , 13, 164	4.8	16
56	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
55	Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. <i>Combination Products in Therapy</i> , 2013 , 3, 25-37		1
54	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 501-5	6.4	12
53	Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. <i>Clinical Cancer Research</i> , 2013 , 19, 138-47	12.9	77
52	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013 , 22, 470-5	3.6	12
51	Gene expression profiling in breast cancer: a clinical perspective. <i>Breast</i> , 2013 , 22, 109-120	3.6	56
50	Issues of banking breast cancer cells to generate mammospheres. <i>Cell and Tissue Banking</i> , 2013 , 14, 153-82		2
49	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. <i>Anti-Cancer Drugs</i> , 2013 , 24, 980-5	2.4	15

48	Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study. <i>Oncologist</i> , 2013 , 18, 924-5	5.7	
47	EMPACT syndrome associated with phenobarbital. <i>Dermatitis</i> , 2013 , 24, 37-9	2.6	7
46	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
45	Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. <i>OncImmunology</i> , 2013 , 2, e25123	7.2	3
44	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013 , 99, e131-e133	1.7	0
43	Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 726-732	1.6	2
42	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
41	Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors. <i>Clinical Nuclear Medicine</i> , 2013 , 38, 354-8	1.7	11
40	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013 , 5, 125-35	1.7	19
39	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 309-15	3.5	35
38	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
37	A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 1113-9	4	125
36	Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012 , 81, 960-72	4.6	28
35	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2526-34	6.1	165
34	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1079-1080	4	2
33	Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2012 , 23, 573-7	2.4	26
32	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28
31	Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13509-e13509	2.2	1

30	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011 , 13, R67	8.3	161
29	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 449-455	2.1	3
28	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011 , 107, 234-9	5.6	71
27	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
26	Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. <i>European Urology</i> , 2011 , 60, 1280-4	10.2	48
25	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 147-54	4.4	20
24	Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 451-8	4.4	26
23	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1455-61	3.5	22
22	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1207-13	3.5	58
21	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1491-7	4	20
20	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011 , 97, 690-2	1.7	11
19	Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. <i>Experimental and Therapeutic Medicine</i> , 2010 , 1, 611-617	2.1	2
18	Castration-resistant prostate cancer: current and emerging treatment strategies. <i>Drugs</i> , 2010 , 70, 983-1000	10.0	77
17	Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. <i>Oncology</i> , 2010 , 78, 369-75	3.6	25
16	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 311-9	4.8	4
15	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
14	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010 , 16, 2526-30	5.6	25
13	Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. <i>Oncology</i> , 2009 , 77 Suppl 1, 23-37	3.6	44

12	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4469-74	2.2	114
11	Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009 , 115, 517-23	6.4	18
10	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009 , 20, 277-80	2.4	7
9	Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1578-80	4.3	44
8	Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. <i>European Urology</i> , 2008 , 54, 1089-94	10.2	106
7	Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R60	8.3	47
6	Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 44-53	2.2	327
5	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. <i>Cancer</i> , 2008 , 112, 75-83	6.4	70
4	Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. <i>Cancer</i> , 2008 , 112, 1147-52	6.4	25
3	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 171-80	7	19
2	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 3091-100	6.1	9
1	Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003 , 89, 349-360	1.7	5